Connect Biopharma Holdings Limited
CNTBNext catalyst
No upcoming catalyst in our data
No upcoming FDA decision, filing or trial readout is on file for CNTB. That does not mean none is planned.
Get an email about CNTB's next catalysts
Track Connect Biopharma Holdings (CNTB) and we email you when an FDA date moves, 7 days and 1 day before the decision when the exact day is known, and when it is announced. Free account, no card.
1 upcoming event in our data (earnings).See the timeline
2 upcoming, 0 past
CNTB Earnings Report
Date estimated from past reporting pattern, not yet confirmed by the company | EPS Est: $-0.27 | FQ end Sep/2026 | Call: tbd
Rademikibart Phase 2 Est. Readout
Estimated primary completion for Rademikibart trial (NCT07705737) in Asthma Acute. Topline data typically follows completion by weeks to months.
Auto-detected: positive
SourceHow CNTB's past catalysts played out
Market Overview
Stock performance and key metrics
Acetaminophen
Patency of the Ductus Arteriosus
NACL
Patency of the Ductus Arteriosus
umbilical cord blood (hUCB) cells
Cerebral Palsy
CBP-201
Moderate to Severe Persistent Asthma
Rademikibart
Asthma Acute
Open-label CBP-307
Moderate to Severe Ulcerative Colitis
Double-Blind CBP-307
Moderate to Severe Ulcerative Colitis
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Acetaminophen | Phase 3 | Patency of the Ductus Arteriosus | - | - |
NACL | Phase 3 | Patency of the Ductus Arteriosus | - | - |
umbilical cord blood (hUCB) cells | Phase 2 | Cerebral Palsy | - | - |
CBP-201 | Phase 2 | Moderate to Severe Persistent Asthma | - | - |
Rademikibart | Phase 2 | Asthma Acute | - | - |
Open-label CBP-307 | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
Double-Blind CBP-307 | Phase 2 | Moderate to Severe Ulcerative Colitis | - | - |
Frequently asked questions
What is in Connect Biopharma Holdings Limited's drug pipeline?→
CatalystAlert tracks 7 drug candidates in Connect Biopharma Holdings Limited's (CNTB) pipeline across Phase 3, Phase 2. Its lead program is Acetaminophen (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Connect Biopharma Holdings Limited's next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Connect Biopharma Holdings Limited (CNTB) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track CNTB biotech catalysts?→
Add CNTB to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Connect Biopharma Holdings Limited's live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.